- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05196412
Screening of Cardiac Arrhythmias With Wrist-worn Aino ECG Cardiac Monitor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study consists of monitoring voluntary subjects with PulseOn Arrhythmia Monitoring System for the period of two weeks. The subjects are recruited mainly through newspaper advertisements. The study is executed in Tampere and Helsinki areas, Finland.
During the two week monitoring time, the subjects are instructed to wear the wrist device continuously, except when taking the device off e.g. for going to sauna or swimming, and for charging. The subjects are instructed to perform a 35-second ECG measurement (recording) in three cases:
- Scheduled recording four times a day
- In case of suspecting arrhythmic event, i.e. feeling symptoms
- In case the wrist device instructs to perform a recording by vibrating and showing an LED light
The data collected in the study is analysed post-hoc. In the post-hoc analysis, the cardiac rhythm assessed automatically from the ECG measurements is visually confirmed by a cardiologist.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Antti Vehkaoja, DSc (tech)
- Phone Number: +358407393181
- Email: antti.vehkaoja@pulseon.fi
Study Locations
-
-
-
Tampere, Finland
- Recruiting
- Tampere Heart Hospital
-
Contact:
- Research coordinator at Heart Hospital
- Phone Number: +358417306125
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for the main study group:
- At least 65 years of age
- Self-assessed ability to use the study devices
- Ability to give informed consent
- Volunteering for the study
Inclusion criteria for the active endurance athlete group:
- Minimum of 10 years of active training of endurance sport (e.g. long distance running, skiing, cycling, triathlon…) and currently an average amount of training of at least 10 hours a week.
- Age: ≥ 50 years
- Self-assessed ability to use the study devices
- Ability to give informed consent
- Volunteering for the study
Exclusion Criteria for both groups:
- Cardiac pacemaker
- Earlier diagnosis of atrial fibrillation
- Inability to give informed consent
- Denial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Main study group
Normal subjects of at least 65 years of age
|
Wearing of the wrist device for a period of two weeks
|
Experimental: Endurance athlete group
Group consists of active endurance athletes of at least 50 years of age
|
Wearing of the wrist device for a period of two weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic performance improvement with continuous optical measurement
Time Frame: Duration of patient measurement, i.e. two weeks
|
Percentual improvement in the performance of detecting previously undiagnosed atrial fibrillation in the study population by the continuous PPG-based heartbeat interval monitoring when compared with relying only on scheduled and symptom -based ECG measurements.
Cardiac rhythm assessed by a cardiologist from the ECG measurements that are made as a result of PPG-based arrhythmia notifications is compared with rhythm assessments made only from the scheduled and symptom-based ECG measurements.
It is evaluated whether more subjects can be diagnosed having atrial fibrillation with the help of continuous PPG-based rhythm monitoring.
|
Duration of patient measurement, i.e. two weeks
|
Validation of the clinical performance of PulseOn Arrhythmia Monitor System in general population by showing the adequacy of the obtained ECG data for clinical decision making.
Time Frame: Duration of patient measurement, i.e. two weeks
|
Data recorded by the study subjects during the two-week study time is assessed by a cardiologist and subjects are classified as having: "no observed arrhythmias", "atrial fibrillation episode(s)", "other potential arrhythmia", or "unconfident assessment" (due to the quality or lack of data).
The percentage of "unconfident assessment" shall be less than 20% of the subjects.
|
Duration of patient measurement, i.e. two weeks
|
Validation of the clinical performance of PulseOn Arrhythmia Monitor System in general population by showing sufficient patient convenience for using the device for the intended duration of two weeks
Time Frame: Duration of patient measurement, i.e. two weeks
|
The feedback from the subjects should show at least grade 3 in a scale of 1-5 for the "comfortability of using the wrist device".
|
Duration of patient measurement, i.e. two weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Showing the benefit of the combined wrist-worn PPG and ECG solution in detecting other cardiac arrhythmias than atrial fibrillation.
Time Frame: Duration of patient measurement, i.e. two weeks
|
The visual ECG-based rhythm annotation made by a cardiologist is compared with simultaneous PPG-algorithm alarm state.
The incidence of notifications for other arrhythmias than atrial fibrilation is reported.
|
Duration of patient measurement, i.e. two weeks
|
Evaluation of the necessity of performing scheduled ECG measurements in addition to ECG measurements triggered by PPG-based arrhythmia notifications for detecting atrial fibrillation.
Time Frame: Duration of patient measurement, i.e. two weeks
|
Evaluation is done by comparing the atrial fibrillation detection outcome when considering only the PPG-triggered and symptom-based ECG measurements or when considering also the scheduled ECG measurements.
The outcome parameter is the number of subjects that would have been left undetected if the scheduled ECG measurements were not taken.
|
Duration of patient measurement, i.e. two weeks
|
Feedback about the usability of the evaluated solution from study subjects.
Time Frame: At the end of the 2-week measurement period
|
Feedback questions in scale of 1-5 and open-ended feedback.
Easiness of use of the wrist device, understandability of the user interface, suitability of the user materials, and unobtrusiveness.
|
At the end of the 2-week measurement period
|
Feedback about the usability of the evaluated solution from study personnel.
Time Frame: At the end of the study i.e. the end of 2022.
|
Feedback questions in scale of 1-5 and open-ended feedback.
Easiness of use of the data management service, suitability of the user materials.
|
At the end of the study i.e. the end of 2022.
|
Quality of the measured ECG signals
Time Frame: Duration of patient measurement, i.e. two weeks
|
Percentage of the ECG measurements classified as inadequate quality for rhythm assessment either an ECG analysis algorithm or by a doctor.
|
Duration of patient measurement, i.e. two weeks
|
Assessment of the subjects' adherence in using the solution.
Time Frame: Duration of patient measurement, i.e. two weeks
|
Analysis of how well the participants will follow the study protocol and do the participants register their ECG in correlation with the wrist device notification.
The outcome parameter is the percentage of scheduled and PPG-based notifications to take an ECG measurement and the variation of the percentage between the subjects.
|
Duration of patient measurement, i.e. two weeks
|
Benefit of optical measurement for the speed of detecting atrial fibrillation
Time Frame: Duration of patient measurement, i.e. two weeks
|
Comparison of the time to the first detection of atrial fibrillation or other arrhythmia when considering PPG-triggered ECG measurements or when considering the scheduled ECG measurements.
|
Duration of patient measurement, i.e. two weeks
|
Evaluation of the accuracy of automatic ECG analysis algorithms when comparing with manual annotations by a cardiologist.
Time Frame: Duration of patient measurement, i.e. two weeks
|
The automated assessment done for the 30-second ECG recordings is compared with the visual assessment to calculate the sensitivity and specificity for each rhythm category.
|
Duration of patient measurement, i.e. two weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vesa Virtanen, PhD (med), Heart Hospital of Tampere University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AinoScreening
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on PulseOn Arrhythmia Monitor device
-
Instituto de Cardiologia do Rio Grande do SulUnknownAcute Myocardial Infarction
-
Stanford UniversityWork of Breathing Study GroupCompletedAsthma | Copd | Respiratory Effort | Contactless Vital Sign MonitoringUnited States
-
Signos IncRecruitingDiabetes Mellitus, Type 2 | Metabolic Syndrome | Insulin Resistance | Weight Loss | Glucose Intolerance | Central Obesity | Metabolic Glucose DisordersUnited States
-
Signos IncRecruitingMetabolic Syndrome | Weight Loss | Glucose Intolerance | Pre-diabetes | Central Obesity | Metabolic Glucose DisordersUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...TerminatedBreast CancerUnited States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedPhysical ActivityUnited States
-
William Beaumont HospitalsCompletedBariatric PatientsUnited States
-
Cardiovascular Research New BrunswickDalhousie University; Horizon Health Network; Cloud DX Inc.; New Brunswick Health... and other collaboratorsRecruiting
-
Cardiovascular Research New BrunswickDalhousie University; Horizon Health Network; Cloud DX Inc.; New Brunswick Health...Recruiting